Evidence outlook
Approved: Rheumatoid Arthritis, COVID-19
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Reliable signal
Also approved (7)
- Giant cell arteritis (GCA) in adult patients
- Polyarticular juvenile idiopathic arthritis (PJIA) in patients 2 years of age and older
- Active systemic juvenile idiopathic arthritis (SJIA) in patients 2 years of age and older
- Cytokine release syndrome (CRS)
- Patients 2 years of age and older with active systemic juvenile idiopathic arthritis
- Avtozma/CT-P47: RA, JIA, Castleman disease, cytokine release syndrome
- Avtozma: all indications of RoActemra (RA, sJIA, pJIA, GCA, etc.)
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT05489224 NCT05489224 · Rheumatoid Arthritis The study was randomized, quadruple-blind, and actively controlled, with 234 participants assigned to CT-P47 and 237 to RoActemra. Its primary clinical endpoint, change in DAS28(ESR) at Week 24, met the prespecified equivalence criterion: the treatment difference was -0.10 with a 90% confidence interval of -0.30 to 0.10, within the predefined margin of -0.6 to 0.5. Registry: NCT05489224 | 3 | Mean Change From Baseline in Disease Activity Score 28 (DAS28) Using Erythrocyte Sedimentation Rate (ESR) at Week 24 2023-06-29 | Mean Change From Baseline in Disease Activity Score 28 (DAS28) Using Erythrocyte Sedimentation Rate (ESR) at Week 24 (Week 24): CT-P47 -3.77 units on a scale (Standard Error 0.12) vs RoActemra -3.67 units on a scale (Standard Error 0.118) | Reliable signal | link ↗ |
View 1 more trial
NCT05725434 NCT05725434 · Rheumatoid Arthritis This was a single-arm study with no control group and no blinding, designed to test how easy the injector device is to use rather than to prove the drug works, so it cannot show comparative evidence either way. Registry: NCT05725434 | 3 | The usability of AI as assessed by patients rating using POST-Self-Injection Assessment Questionnaire (SIAQ) at Week 2. 2023-04-01 | 12-week, single-arm, open-label Phase 3 usability study: Post-Self-Injection Assessment Questionnaire (POST-SIAQ) domain scores at Week 2 exceeded 8/10 for all domains except self-confidence (7.11) and satisfaction with self-injection (7.98); the study is reported to have met its primary usability endpoint, with no autoinjector malfunctions and no new safety signals. | Weak signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.
Phase 3 (2)
What this study did
What this study did
Phase 1 (2)
What this study did
What this study did
Appears in other studies (1)
Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.
Phase 2/3 (1)
What this study did
Competitive landscape
This drug's own stage for COVID-19: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| CT-P47 (tocilizumab) (Avtozma): this drug | Approved | Monoclonal antibody | IL-6R antagonist | not yet graded | No reviewed efficacy summary in this indication | |
| Baricitinib (Olumiant) | Approved | Small molecule | JAK, JAK1/2 | not yet graded | No reviewed efficacy summary in this indication | |
| BAT1806 (Tofidence) | Approved | Monoclonal antibody | IL-6 receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Elasomeran (Spikevax) | Approved | Vaccine | SARS-CoV-2 spike protein | Reliable signal | No reviewed efficacy summary in this indication | |
| Tocilizumab (Actemra / RoActemra) | Approved | Monoclonal antibody | IL-6 receptor | Partial signal | NCT04409262: Time to Hospital Discharge or "Ready for Discharge" up to Day 28 (Up to Day 28): Remdesivir + Placebo (RDV+Placebo) - mITT Population 14 days (95% CI 11 to 16) | Remdesivir + Tocilizumab (RDV+TCZ) - mITT Population 14 days (95% CI 12 to 15) missed NCT04372186: Cumulative Proportion of Participants Who Died or Required Mechanical Ventilation by Day 28 (Up to Day 28): Tocilizumab 12.04 Percentage of Participants (95% CI 8.52 to 16.86) | Placebo 19.26 Percentage of Participants (95% CI 13.34 to 27.36) | |
| Azvudine (FNC) | Phase 3 | Small molecule | HIV reverse transcriptase | not yet graded | No reviewed efficacy summary in this indication | |
| Ibuzatrelvir | Phase 3 | Small molecule | SARS-CoV-2 3CL protease | not yet graded | No reviewed efficacy summary in this indication | |
| Levilimab (Ilsira) | Phase 3 | Monoclonal antibody | IL-6 receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Masitinib | Phase 2 | Small molecule | KIT (c-Kit), also PDGFR and Lyn/Fyn kinases | not yet graded | No reviewed efficacy summary in this indication | |
| GSK4396687 | —(overall) | Vaccine | — | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
No upcoming readouts on record for this asset.
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent